CRSP
CRISPR Therapeutics AG
$51.60
-0.46%
$5.0B
No data for this timeframe.
Vol
Market Cap$5.0B
Cap SizeMid Cap
Analyst ConsensusBuy (59%)
Insider Activity0B / 10S
Insider Net $-$2.8M
Reddit Sentiment50° Neutral
SEC Reports4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. V8·CIK 0001674416·Prev Close $51.84
Recent Activity
Jun 5, 2026
Insider
George Simeon sold 13,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Behbahani Ali sold 13,000 shares
Director @ $0.00 ($0.00)
Jun 5, 2026
Insider
Fardis Maria sold 13,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
SEC
CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items incl
8-K — Impact 3/10
Jun 3, 2026
short_volume
Short Volume: CRSP — 58.9% short (0.3M / 0.5M)
Short: 313,362 | Exempt: 333 | TRF Vol: 531,807 | Short Ratio: 58.9% | Off-exchange volume (dark poo
May 4, 2026
SEC
CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total revenue of $1.5M was up
8-K — Impact 5/10
Apr 21, 2026
SEC
CRISPR Therapeutics AG filed a definitive proxy statement for its 2026 Annual General Meeting, seeking shareholder appro
DEFA14A — Impact 3/10
Price Targets
$82.24
+59.7% upside
Strong Buy
Current $51.48
Low $33.00
Median $76.00
High $291.00
21 analysts
$33.00
$291.00
Analyst Ratings
7Strong Buy
12Buy
12Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform → Market Perform |
| May 6, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| Feb 17, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Feb 13, 2026 | TD Cowen | MAINTAIN | Hold → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.18 ▲ +2.9% | $-1.44 — $-0.81 | 8% YoY | 19 |
| Next Q | $-1.18 | $-1.72 — $-0.35 | -1% YoY | 19 |
| Current FY | $-4.79 | $-6.37 — $-3.35 | 26% YoY | 22 |
| Next FY | $-3.86 ▲ +4.9% | $-6.23 — $-0.68 | 19% YoY | 21 |
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | George Simeon | A | $0.00 |
| Jun 5, 2026 | Behbahani Ali | A | $0.00 |
| Jun 5, 2026 | Fardis Maria | A | $0.00 |
| Jun 5, 2026 | Mahatme Sandesh | A | $0.00 |
| Jun 5, 2026 | Fleming Harold | A | $0.00 |
Reddit Sentiment
50°▲
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
14 unique insiders with 10 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | George Simeon | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Behbahani Ali | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Fardis Maria | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Mahatme Sandesh | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Fleming Harold Edward | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | High Katherine A | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Greene John | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Morrison Briggs | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Rommel Christian | Director | A | 13,000 | $0.00 | $0.00 |
| Jun 5, 2026 | Treco Douglas A | Director | A | 13,000 | $0.00 | $0.00 |
| May 29, 2026 | Prasad Raju | Chief Financial Officer | A | 19,500 | $0.00 | $0.00 |
| May 29, 2026 | KASINGER JAMES R. | General Counsel and Secretary | A | 17,000 | $0.00 | $0.00 |
| May 29, 2026 | Patel Naimish | Chief Medical Officer | A | 22,000 | $0.00 | $0.00 |
| May 29, 2026 | Patel Naimish | Chief Medical Officer | SELL | 3,786 | $55.62 | $210.6K |
| May 28, 2026 | Patel Naimish | Chief Medical Officer | M | 10,000 | $0.00 | $0.00 |
| May 28, 2026 | Patel Naimish | Chief Medical Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 23, 2026 | KASINGER JAMES R. | General Counsel and Secretary | SELL | 3,182 | $46.78 | $148.9K |
| Mar 23, 2026 | Kulkarni Samarth | Chief Executive Officer | SELL | 10,020 | $46.78 | $468.7K |
| Mar 23, 2026 | Prasad Raju | Chief Financial Officer | SELL | 3,708 | $46.78 | $173.5K |
| Mar 20, 2026 | Patel Naimish | Chief Medical Officer | A | 30,000 | $0.00 | $0.00 |
| Mar 20, 2026 | Patel Naimish | Chief Medical Officer | A | 38,499 | $0.00 | $0.00 |
| Mar 20, 2026 | Prasad Raju | Chief Financial Officer | M | 6,250 | $0.00 | $0.00 |
| Mar 20, 2026 | Kulkarni Samarth | Chief Executive Officer | M | 19,687 | $0.00 | $0.00 |
| Mar 20, 2026 | Prasad Raju | Chief Financial Officer | A | 38,499 | $0.00 | $0.00 |
| Mar 20, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 6,250 | $0.00 | $0.00 |
| Mar 20, 2026 | KASINGER JAMES R. | General Counsel and Secretary | A | 25,000 | $0.00 | $0.00 |
| Mar 20, 2026 | KASINGER JAMES R. | General Counsel and Secretary | A | 38,499 | $0.00 | $0.00 |
| Mar 20, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 6,250 | $0.00 | $0.00 |
| Mar 20, 2026 | Kulkarni Samarth | Chief Executive Officer | A | 114,249 | $0.00 | $0.00 |
| Mar 20, 2026 | Kulkarni Samarth | Chief Executive Officer | M | 19,687 | $0.00 | $0.00 |
| Mar 20, 2026 | Kulkarni Samarth | Chief Executive Officer | A | 81,875 | $0.00 | $0.00 |
| Mar 20, 2026 | Prasad Raju | Chief Financial Officer | M | 6,250 | $0.00 | $0.00 |
| Mar 20, 2026 | Prasad Raju | Chief Financial Officer | A | 27,500 | $0.00 | $0.00 |
| Mar 16, 2026 | Kulkarni Samarth | Chief Executive Officer | SELL | 10,349 | $48.26 | $499.4K |
| Mar 16, 2026 | Prasad Raju | Chief Financial Officer | SELL | 5,848 | $48.26 | $282.2K |
| Mar 16, 2026 | Patel Naimish | Chief Medical Officer | SELL | 3,150 | $48.26 | $152.0K |
| Mar 16, 2026 | Prasad Raju | Chief Financial Officer | G | 750 | $0.00 | $0.00 |
| Mar 16, 2026 | KASINGER JAMES R. | General Counsel and Secretary | SELL | 3,450 | $48.26 | $166.5K |
| Mar 14, 2026 | Patel Naimish | Chief Medical Officer | M | 8,125 | $0.00 | $0.00 |
| Mar 14, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 6,875 | $0.00 | $0.00 |
| Mar 14, 2026 | Kulkarni Samarth | Chief Executive Officer | M | 20,625 | $0.00 | $0.00 |
| Mar 14, 2026 | Kulkarni Samarth | Chief Executive Officer | M | 20,625 | $0.00 | $0.00 |
| Mar 14, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 6,875 | $0.00 | $0.00 |
| Mar 14, 2026 | Patel Naimish | Chief Medical Officer | M | 8,125 | $0.00 | $0.00 |
| Mar 14, 2026 | Prasad Raju | Chief Financial Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 14, 2026 | Prasad Raju | Chief Financial Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 11, 2026 | KASINGER JAMES R. | General Counsel and Secretary | SELL | 2,800 | $52.80 | $147.8K |
| Mar 11, 2026 | Kulkarni Samarth | Chief Executive Officer | SELL | 9,798 | $52.80 | $517.3K |
| Mar 10, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 5,500 | $0.00 | $0.00 |
| Mar 10, 2026 | KASINGER JAMES R. | General Counsel and Secretary | M | 5,500 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
3/10
CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approve
Jun 4, 2026
BEARISH
8-K
5/10
CRISPR Therapeutics reported Q1 2026 EPS of -$1.28, missing consensus of -$1.14 by 12.3%. Total reve
May 4, 2026
NEUTRAL
DEFA14A
3/10
CRISPR Therapeutics AG filed a definitive proxy statement for its 2026 Annual General Meeting, seeki
Apr 21, 2026
NEUTRAL
CLUSTER
3/10
CRISPR Therapeutics CFO Prasad Raju sold $173,460 worth of shares in an open-market transaction, whi
Mar 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (59% buy). Based on 32 analysts: 7 strong buy, 12 buy, 12 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$82.24 mean target
+59.7% upside
Strong Buy (2.04)
$33.00 Low
$291.00 High
| Metric | Value |
|---|---|
| Current Price | $51.48 |
| Target Low | $33.00 |
| Target Mean | $82.24 |
| Target Median | $76.00 |
| Target High | $291.00 |
| # Analysts | 21 |
| Recommendation | Strong Buy (2.04) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.18 | $-1.44 | $-0.81 | 8.3% | +2.9% | 11↑ 6↓ | $0.0B | 620.1% | 19 |
| Next Q 2026-09-30 |
$-1.18 | $-1.72 | $-0.35 | -0.9% | +0.1% | 10↑ 7↓ | $0.0B | 1640.8% | 19 |
| Current FY 2026-12-31 |
$-4.79 | $-6.37 | $-3.35 | 26.0% | -0.5% | 10↑ 9↓ | $0.0B | 1152.0% | 22 |
| Next FY 2027-12-31 |
$-3.86 | $-6.23 | $-0.68 | 19.3% | +4.9% | 9↑ 6↓ | $0.2B | 245.2% | 21 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.183 | |
| 7d ago | $-1.183 | |
| 30d ago | $-1.219 | +0.035 |
| 60d ago | $-1.240 | +0.057 |
| 90d ago | $-1.241 | +0.058 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Bernstein | MAINTAIN | Market Perform | Market Perform |
| May 6, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 17, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Feb 13, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 13, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Dec 23, 2025 | Needham | REITERATE | Buy | Buy |
| Dec 23, 2025 | Citizens | REITERATE | Market Outperform | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 12 | 12 | 1 | 0 | 59% | |
| May 1, 2026 | 9 | 13 | 12 | 1 | 0 | 63% | |
| Apr 1, 2026 | 9 | 13 | 12 | 1 | 0 | 63% | |
| Mar 1, 2026 | 9 | 13 | 12 | 1 | 0 | 63% | |
| Feb 1, 2026 | 9 | 13 | 12 | 1 | 0 | 63% | |
| Jan 1, 2026 | 9 | 13 | 13 | 1 | 0 | 61% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
10 mentions
2 bullish
2 bearish
9 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 2, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Jun 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 30, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 5, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
What if the next AI is genetics?
▲ 1
💬 0
⚡ 0.5
#CRSP $200k all-in
▲ 1
💬 0
⚡ 0.5
Rate my starter portfolio and offer some advice
▲ 1
💬 1
⚡ 0.5
Are you Bearish or Bullish on CRSP?
▲ 1
💬 1
⚡ 0.0
Jun 3, 2026
short_volume
Short Volume: CRSP — 58.9% short (0.3M / 0.5M)
Short: 313,362 | Exempt: 333 | TRF Vol: 531,807 | Short Ratio: 58.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
Clinical Trial
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Phase Phase 2 — COMPLETED
Jun 2, 2026
clinical_trial_readout
Results Pending: CTX131 (Phase 2) — Completed 83d ago
Trial: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Sponsor: CRISPR Therapeutics
Jun 2, 2026
short_volume
Short Volume: CRSP — 57.7% short (0.4M / 0.7M)
Short: 384,625 | Exempt: 505 | TRF Vol: 666,897 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: CRSP — 57.8% short (0.4M / 0.7M)
Short: 391,000 | Exempt: 19,367 | TRF Vol: 676,911 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: CRSP — 56.4% short (0.5M / 1.0M)
Short: 548,280 | Exempt: 501 | TRF Vol: 972,040 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: CRSP — 55.9% short (0.4M / 0.7M)
Short: 414,678 | Exempt: 3,372 | TRF Vol: 742,355 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: CRSP — 63.7% short (0.5M / 0.7M)
Short: 460,311 | Exempt: 121 | TRF Vol: 722,368 | Short Ratio: 63.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: CRSP — 62.7% short (0.5M / 0.8M)
Short: 527,644 | Exempt: 2,258 | TRF Vol: 841,294 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: CRSP — 79.1% short (0.6M / 0.8M)
Short: 626,029 | Exempt: 798 | TRF Vol: 791,176 | Short Ratio: 79.1% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: CRSP — 63.4% short (0.4M / 0.6M)
Short: 411,326 | Exempt: 94 | TRF Vol: 648,289 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: CRSP — 672,023 shares ($35.4M) failed to deliver
Settlement: 20260514, Price: $52.75, FTD Value: $35,449,213.25, CRISPR THERAPEUTICS AG NAMEN A
May 12, 2026
short_interest
FTD: CRSP — 11,890 shares ($0.6M) failed to deliver
Settlement: 20260512, Price: $54.01, FTD Value: $642,178.9, CRISPR THERAPEUTICS AG NAMEN A
May 11, 2026
earnings_calendar
CRSP Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
short_volume
Short Volume: CRSP — 61.4% short (0.4M / 0.7M)
Short: 436,757 | Exempt: 1,189 | TRF Vol: 710,847 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
May 6, 2026
other
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
<p align="justify">ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of